ISMRM23 - Interventional MR

ISMRM & ISMRT Annual Meeting & Exhibition • 03-08 June 2023 • Toronto, ON, Canada

Interventional MR

ISMRT Education Session

ORGANIZERS: Huijun (Vicky) Liao, Caron Murray, Brandy Reed, Adam Scotson, Nancy Talbot

Sunday, 04 June 2023

Constitution Hall 106

10:00 - 11:30

Moderators: Caron Murray & Brandy Reed

Session Number: ISMRT-07

CE Credit

Session Number: ISMRT-07

Overview
This session will discuss MR-guided ultrasound for both Parkinson's disease and prostate cancer. The process of translating research to clinical in the interventional field will also be discussed.

Target Audience
Radiographers, MR technologists, radiologists, clinicians, and scientists interested in learning about the clinical translation of technological advances in MRI, particularly in the fields of interventional imaging.

Educational Objectives
As a result of attending this course, participants should be able to:
- Describe MR-guided ultrasound for Parkinson's disease;
- Describe MR-guided ultrasound for prostate cancer; and
- Explain the process of translating research to clinical in the interventional field.

10:00		Interventional MRI: Translating Research to Clinical Service View Presentation Video R. Jason Stafford Keywords: Physics & Engineering: Interventional, Transferable skills: Safety, Contrast mechanisms: Thermometry Interventional and intraoperative MRI deviate from traditional diagnostic use of MRI and can require special environments, equipment, acquisitions and safety considerations when translated into clinical services. Here we briefly overview several examples of clinical iMRI/ioMRI offered in an oncology setting.
10:30		MRgUS Brain: Parkinson's Disease View Presentation Video Kullervo Hynynen
11:00		MR guided Focused Ultrasound Surgery (MRgFUS) for Prostate Cancer View Presentation Video Sangeet Ghai Keywords: Body: Body Focal therapy (FT), where a specific clinically significant PCa (csPCa) is ablated, is a treatment option for localized intermediate-risk disease. The aim of FT is to eradicate csPCa while minimizing morbidity associated with whole-gland treatment. MRI allows spatial resolution in all 3 planes for precise treatment definition. Additionally, MR thermography provides thermal feedback during treatment. Non-perfused volume can be assessed following treatment providing assessment of the ablated area. The ExAblate 2100 Prostate (Insightec Inc., Haifa) is a transrectal, MRI guided focused ultrasound (MRgFUS) system. This presentation will outline the technique and existing literature of MRgFUS treatment for intermediate risk PCa.